Amundi Pioneer Asset Management Inc. purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 202,690 shares of the medical research company’s stock, valued at approximately $5,311,000. Amundi Pioneer Asset Management Inc. owned approximately 0.37% of Accelerate Diagnostics at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of AXDX. Artal Group S.A. raised its stake in Accelerate Diagnostics by 150.0% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the medical research company’s stock valued at $13,100,000 after buying an additional 300,000 shares in the last quarter. Next Century Growth Investors LLC increased its position in shares of Accelerate Diagnostics by 30.5% during the fourth quarter. Next Century Growth Investors LLC now owns 660,020 shares of the medical research company’s stock worth $17,292,000 after purchasing an additional 154,387 shares in the last quarter. AXA increased its position in shares of Accelerate Diagnostics by 40.2% during the third quarter. AXA now owns 432,647 shares of the medical research company’s stock worth $9,713,000 after purchasing an additional 124,035 shares in the last quarter. Lombard Odier Asset Management USA Corp increased its position in shares of Accelerate Diagnostics by 420.4% during the fourth quarter. Lombard Odier Asset Management USA Corp now owns 130,094 shares of the medical research company’s stock worth $3,408,000 after purchasing an additional 105,094 shares in the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in shares of Accelerate Diagnostics during the fourth quarter worth about $2,584,000. Institutional investors own 44.86% of the company’s stock.
A number of research firms have recently commented on AXDX. BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. BTIG Research reiterated a “hold” rating on shares of Accelerate Diagnostics in a research report on Sunday, February 18th. Finally, ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. Accelerate Diagnostics presently has an average rating of “Hold” and an average price target of $33.00.
In related news, Director Jack W. Schuler purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $24.95 per share, for a total transaction of $499,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jack W. Schuler purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average price of $25.21 per share, for a total transaction of $252,100.00. The disclosure for this purchase can be found here. Insiders purchased a total of 45,100 shares of company stock worth $1,130,850 in the last 90 days. 50.00% of the stock is currently owned by insiders.
AXDX stock traded down $0.15 during trading on Thursday, hitting $24.35. The company had a trading volume of 155,700 shares, compared to its average volume of 252,694. The stock has a market capitalization of $1,349.55, a PE ratio of -20.99 and a beta of 2.13. Accelerate Diagnostics, Inc. has a 1-year low of $16.75 and a 1-year high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. The firm had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. equities research analysts predict that Accelerate Diagnostics, Inc. will post -1.2 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “202,690 Shares in Accelerate Diagnostics, Inc. (AXDX) Purchased by Amundi Pioneer Asset Management Inc.” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://macondaily.com/2018/04/12/amundi-pioneer-asset-management-inc-takes-position-in-accelerate-diagnostics-inc-axdx-updated-updated-updated.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.